The Global Glycated Albumin Assay Market Growth Accelerated By Rising Diabetic Population
Glycated albumin refers to a form of albumin that is non-enzymatically bound to glucose. The glycated albumin assay aids in monitoring glucose control in patients with diabetes by measuring the level of glycated albumin in the blood. It provides an estimate of average blood glucose levels over a shorter period of around 2-3 weeks as compared to the hemoglobin A1C test which indicates average blood glucose levels over 3 months. The global glycated albumin assay market offers convenient glycated albumin test kits for point-of-care testing without the need for elaborate infrastructure.
The global Glycated Albumin Assay Market is estimated to be valued at US$ 571.0 Mn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
The rising prevalence of diabetes across the globe primarily drives the growth of the glycated albumin assay market. As per estimates, approximately 537 million adults were living with diabetes in 2021 worldwide and the number is projected to rise to 783 million by 2045. Higher glycated albumin levels are associated with increased risk of diabetes complications affecting eyes, kidneys, heart, and nerves. Therefore, regular monitoring of glycated albumin assists healthcare practitioners in managing diabetes and prevents further damage. Recent advancements in point-of-care testing technologies have made the glycated albumin assay convenient for use in alternate care settings like ambulances, medically underserved areas, and at home, thereby increasing accessibility and supporting market expansion.
Segment Analysis
The global glycated albumin assay market is dominated by the enzymatic method segment due to its ability to provide accurate and reproducible results. The enzymatic method utilizes glycated albumin-specific enzymes and chromogenic substrates to measure glycated albumin levels. It is considered the gold standard technique for glycated albumin testing as it specifically measures only glycated isoforms without interference from non-glycated albumin and other substances.
Key Takeaways
The global Glycated Albumin Assay Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The global glycated albumin Assay Market is estimated to be valued at US$ 571.0 Mn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030.
Regional analysis: Asia Pacific region is expected to grow the fastest in the glycated albumin assay market during the forecast period. This is attributed to rising diabetes prevalence, increasing healthcare expenditure, a growing geriatric population, and high demand for diabetes management and care in major Asia Pacific countries like India and China.
Key players analysis: Key players operating in the glycated albumin assay market are Asahi Kasei Pharma Corporation, Weldon Biotech Inc., Abbexa Ltd., Laboratory Corporation of America, Biocompare, EFK Diagnostics, Elabscience Biotechnology Inc., Abbot, Diazyme Laboratories Inc., Abnova Corporation, BSBE, Maccura Biotechnology Co., Ltd., LifeSpan BioSciences Inc., Biomatik, Geno Technology Inc., AMS Biotechnology (Europe) Limited, Epinex Diagnostics Inc., and DxGen Corp.
Get More Insights On This Topic: https://www.pressreleasebulletin.com/diagnosing-and-preventing-diabetes-through-glycated-albumin-measurement-is-driven-by-growing-prevalence-of-diabetes/
Comments
Post a Comment